Size | Price | Stock |
---|---|---|
5mg | $38 | In-stock |
10mg | $60 | In-stock |
20mg | $70 | In-stock |
50mg | $84 | In-stock |
100mg | $108 | In-stock |
200mg | $144 | In-stock |
500mg | $216 | In-stock |
1g | $300 | In-stock |
2g | $540 | In-stock |
5 g | Get quote | |
10 g | Get quote | |
We match the lowest price on market. |
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
Cat. No. : | HY-10162 |
M.Wt: | 434.46 |
Formula: | C24H23FN4O3 |
Purity: | >98 % |
Solubility: | DMSO : 100 mg/mL (230.17 mM; Need ultrasonic); DMF : 50 mg/mL (115.09 mM; Need ultrasonic); Ethanol : 3.12 mg/mL (7.18 mM; ultrasonic and warming and heat to 60°C) |
Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4]. IC50 & Target: IC50: 5/1 nM (PARP-1/2)[1] In Vitro: Olaparib (AZD2281) is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Olaparib is applied to SW620 cell lysates, and identified the IC50 for PARP-1 inhibition to be around 6 nM and the total ablation of PARP-1 activity to be at concentrations of 30−100 nM[1]. In Vivo: Animals bearing SW620 xenografted tumors are treated with Olaparib (10 mg/kg, p.o.) in combination with NSC 362856 (TMZ) (50 mg/kg, p.o.) once daily for 5 consecutive days, after which the tumors are left to grow out[1]. Olaparib increases vascular perfusion in Calu-6 tumors established in a DWC model. Administration of olaparib(50 mg/kg, p.o.) as a single agent (top panel) or in combination with radiation (bottom panel) results in an increase in fluorescence intensity in the Calu-6 tumors[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.